肝外胆管癌中血管内皮生长因子C(VEGF-C)的表达及意义

目的 研究肝外胆管癌中VEGF-C的表达情况及其临床意义。方法 应用免疫组化Envision二步法测定32例肝外胆管癌和7例正常胆管组织VEGF-C的表达。结果 VEGF-C在肝外胆管癌和7例正常胆管组织中阳性表达率分别为53．13％，0％。胆管癌组织与正常胆管组织VEGF-C表达水平之间有显著性差异，且VEGF-C表达与胆管癌的分化程度、肿瘤大小和淋巴结转移有关。结论 VEGF-C在胆管癌的表达可促进胆管癌淋巴结的转移，对判断胆管癌淋巴结转移、评估预后有一定意义。     

周围型肺腺癌CT、病理征象与肿瘤淋巴管密度及淋巴转移相关基因表达关系的研究

目的研究周围型肺腺癌的CT、病理征象与肿瘤组织VEGF-C、VEGFR-3表达及淋巴管生成的相关性。方法搜集40例经手术病理证实的肺腺癌,术前均行CT平扫及增强扫描,对肿瘤标本行SP免疫组化染色,根据其阳性表达计数阳性细胞数及淋巴管密度(LMVD),分析肺腺癌某些CT、病理征象与VEGF-C、VEGFR-3表达,LMVD值间的关系。结果淋巴结增大、转移及其它一些CT表现与VEGF-C、VEGFR-3过表达及LMVD值有密切相关性;肿瘤组织的VEGF-C、VEGFR-3表达与LMVD值亦有相关性。结论肺腺癌淋巴结增大等CT征象与VEGF-C、VEGFR-3表达及淋巴管生成具有相关性。     

血管内皮生长因子及其受体在大鼠胃癌组织中的表达

目的探讨癌细胞淋巴道转移机制，观察VEGF-C及其受体Flt-4在大鼠胃癌组织中的表达。方法用免疫组化法检测大鼠胃癌组织的癌细胞和淋巴管内皮细胞对VEGF-C和Flt-4的表达。结果VEGF-C和Flt-4在癌细胞的胞浆均可见阳性表达；淋巴管内皮细胞上仅见到Flt-4的阳性表达。结论①Flt-4与VEGF-C在胃癌细胞的表达正相关，可能与肿瘤的浸润有关。②推测VEGF-C可能通过其受体Flt-4诱导胃癌组织淋巴管发生。     

Evaluation of stromal metalloproteinases and vascular endothelial growth factors in a spontaneous metastasis model

This study aims to investigate MMP2 and MT1-MMP protein as well as VEGF-C and VEGF-D mRNA expression in tumor cells and distant organs considered to be targets for metastasis in a tumor spontaneous metastasis model previously described. Cultured tumor cells, able to express pro-MMP2, MMP2, pro-MMP9, and MT1-MMP, develop tumor growth and metastasis, mainly in the liver and spleen, when they are injected in the mammary pad gland of Wistar rats. Immunohistochemical studies of tumor masses showed small groups of tumor cells staining for MT1-MMP but not for MMP2. In the liver, tumor metastatic foci and a stromal positive staining for both MMP2 and MT1-MMP were shown. The spleen and lymph nodes, with only scattered metastatic cells, did not show MMPs immunostaining. Using RT-PCR, a significantly higher VEGF-C and VEGF-D gene expression was shown in the liver of tumor-bearing rats respect to normal rats, whereas spleen and lymph nodes did not show significant differences in mRNA VEGF-C/D levels. Taken together, our results suggest that the stroma microenvironment of target organs for metastasis has the ability to produce MMPs and VEGFs that facilitate the anchorage of tumor cells and promote tumor cell growth and angiogenesis.     

人胃癌组织中VEGF-C及其受体Flt-4的表达

目的：观察VEGF-C和Fit-4在胃癌组织及淋巴管的表达，探讨癌细胞淋巴管转移机理。方法：用免疫组化方法检测人胃癌早期和进展期癌细胞和淋巴管VEGF-C和Fit-4的表达情况。结果：在各期胃癌的癌细胞中均见到VEGF-C和Fit-4阳性表达，淋巴管内皮细胞仅见到Fit-4阳性表达；进展期胃癌两种蛋白的表达率和表达强度都高于早期癌。结论：癌细胞VEGF-C和Fit-4的表达与肿瘤进展呈正相关；淋巴管上Fit-4的表达也与胃癌的进展呈正相关。推测VEGF-C可能通过其受体Fit-4诱导胃癌组织淋巴管发生。     

VEGF-C和flt-4在肺腺癌中的表达及其临床意义

目的研究转移相关基因VEGF-C、flt-4在肺腺癌中的表达及其临床意义.方法应用免疫组化方法检测10例正常黏膜组织、10例癌旁组织、56例肺腺癌中的VEGF-C、flt-4的表达情况.结果Flt-4主要在淋巴管内皮细胞中表达.VEGF-C在正常黏膜组织、癌旁组织呈弱阳性反应,在肺腺癌组织中VEGF-C表达强阳性;在高分化组与低分化组之间差异有显著性;且晚期病例VEGF-C表达高于早期病例(P＜0.05);淋巴结转移组VEGF-C阳性率明显高于无淋巴结转移组.VEGF-C高表达组术后3年生存率(23.3%)显著低于低表达组(54.5%,P＜0.05).结论VEGF-C与肺腺癌发生、发展及淋巴结转移、预后密切相关.     

VEGF-C、FLT-4、cPKC在肺癌中的表达及意义

 目的　研究转移相关基因VEGF C、FLT 4、cPKC在肺癌中的表达及其临床意义。方法　应用免疫组化方法检测 93例肺癌中的VEGF C、FLT 4、cPKC的表达情况。结果　VEGF C、FLT 4在肺癌的不同组织类型之间无明显差异 ;cPKC在高分化组与低分化组之间有统计学意义 ;但晚期病例三者表达均高于早期病例 ;三者的阳性表达率在淋巴结转移组明显高于无淋巴结转移组。结论　VEGF C、FLT 4、cPKC与肺癌的淋巴结转移密切相关 ,三者之间有高度的相关性     

甲状腺癌淋巴管生成因子表达与淋巴结转移关系的研究

目的研究淋巴管生成因子(VEGF-C)在甲状腺癌中的表达及其与淋巴结转移的关系.方法应用免疫组化S-P法检测44例甲状腺癌中VEGF-C的表达情况,并以17例癌旁正常甲状腺组织作对照.结果 VEGF-C在甲状腺癌中有高水平表达(81.8%),其中乳头状癌阳性表达(88.9%)高于其他类型,有淋巴结转移组VEGF-C阳性率(92.0%)明显高于无淋巴结转移组(68.4%,P＜0.05).9例死亡病例中7例为阳性表达.结论 VEGF-C表达与甲状腺癌病理分型及预后可能有一定关系,与甲状腺癌淋巴结转移密切相关.     

VEGF-C/Flt4系统在甲状腺乳头状癌中的表达及其与淋巴道转移关系的研究

目的 探讨VEGF-C、Flt4在甲状腺乳头状癌中的表达及其与淋巴道转移的关系。方法 用免疫组化SP法检测44例甲状腺乳头状癌及其癌旁组织vEGF-C、F1t4表达情况。结果 44例甲状腺乳头状癌组织vECE-C、Flt4阳性率分别为65．9％（29／44）和61．4％（29／44），两者阳性率在淋巴道转移组均显著高于无转移组（P〈0．05），癌组织中Flt4阳性微脉管数在淋巴道转移组显著高于无转移组（P〈0．05）；在无淋巴结转移组，VEGF-C、Flt4的表达分别为50％（12／24）和45．8％（11／24）；VEGF-C和Flt4表达情况一致的病例占总病例数的90．91％（40／44）。结论VEGF-C／Fk4系统参与了甲状腺乳头状癌淋巴道转移过程，测定肿瘤组织vEGF-C、Flt4表达及计数Flt4阳性微脉管有助于预测甲状腺乳头状癌是否伴淋巴道转移；对于无淋巴结转移而vEGF-C和Flt4呈高表达的病例，必须密切随访观察；vEGF-C可诱导并提高Flt4的表达，共同促进肿瘤的淋巴道转移。     

Predictive role of the overexpression for CXCR4, C-Met,and VEGF-C among breast cancer patients: A meta-analysis

BackgroundThe overexpression of CXCR4, C-Met and VEGF-C present widely in breast tumors, they may be markers of resistance to treatment. However, the studies are still controversial. Thus, this meta-analysis aims to research the relationship between the overexpression of CXCR4, C-Met, VEGF-C and clinical prognosis among breast cancer patients.MethodsPubMed and EMBASE databases were searched for eligible literature. The outcomes of interest were progression-free survival (PFS), relapse-free survival (RFS) and overall survival (OS). All tests of statistical significance were two sided.ResultsA total of 7830 patients from 28 eligible studies were assessed. The overexpression of the CXCR4 and C-Met both implied significantly worse PFS compared with normal expression [HR = 2.56, 95% CI = 1.34–4.91, P = 0.005; and HR = 1.63 95% CI = 1.20–2.22, P = 0.002]. Meanwhile, if patients had high expression of CXCR4, they would have worse OS [HR = 2.56 95% CI = 1.52–4.31, P = 0.000]. However, the overexpression of C-Met did not relate to OS for breast cancer patients [HR = 1.16, 95% CI = 0.69–1.95, P = 0.570]. Meanwhile, no statistically significant different was observed with respect to PFS and OS between VEGF-C overexpression and normal expression [HR = 0.99, 95% CI = 0.64–1.52, P = 0.968; and HR = 0.76, 95% CI = 0.43–1.33, P = 0.333].ConclusionsOur meta-analysis showed that CXCR4 and C-Met were efficient prognostic factors for breast cancer. Nevertheless, highly expressing VEGF-C was not related to progression-free survival and overall survival. Due to the small samples and insufficient date, further studies should be conducted to clarify the association between the overexpression of CXCR4 or C-Met or VEGF-C and the prognosis about breast cancer patients.